Quick Answer
Arcus Biosciences, Inc. reported Long-Term Debt of $99.00 million for fiscal year 2025.
Arcus Biosciences, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $99.00M | +106.2% |
| 2024 | $48.00M | — |
| 2023 | $0.00 | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $98.00M | +108.5% | +1.0% |
| June 30, 2025 | $97.00M | — | +102.1% |
| March 31, 2025 | $48.00M | — | +0.0% |
| December 31, 2024 | $48.00M | — | +2.1% |
| September 30, 2024 | $47.00M | — | — |
| December 31, 2023 | $0.00 | — | — |
- Arcus Biosciences, Inc. showed an increase of +106.2% in Long-Term Debt compared to the prior fiscal year.
- The most recent figure is from Arcus Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: